## Review Articles

- **The Therapeutic Potential of Modifying Inflammasomes and NOD-Like Receptors**  
  *Francesco Di Virgilio*  
  Page: 872

- **Adenosine Kinase: Exploitation for Therapeutic Gain**  
  *Detlev Boison*  
  Page: 906

- **Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects**  
  *Jörg König, Fabian Müller, and Martin F. Fromm*  
  Page: 944

- **Pharmacogenetics and Cardiovascular Disease—Implications for Personalized Medicine**  
  *Julie A. Johnson and Larisa H. Cavallari*  
  Page: 987

- **The Prostanoid EP4 Receptor and Its Signaling Pathway**  
  *Utako Yokoyama, Kousaku Iwatsubo, Masanari Umemura, Takayuki Fujita, and Yoshihiro Ishikawa*  
  Page: 1010

- **Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs**  
  *Elisabet I. Nielsen and Lena E. Friberg*  
  Page: 1053

- **The Pharmacology of Regenerative Medicine**  
  *George J. Christ, Justin M. Saul, Mark E. Furth, and Karl-Erik Andersson*  
  Page: 1091

## IUPHAR Nomenclature Report

International Union of Basic and Clinical Pharmacology. LXXXVIII. G Protein-Coupled Receptor List: Recommendations for New Pairings with Cognate Ligands  
Page: 967

## Erratum

Correction to “Exchange Protein Directly Activated by cAMP (epac): A Multidomain cAMP Mediator in the Regulation of Diverse Biological Functions”  
Page: 1134

---

*About the cover:* Upon activation of the EP4 receptor by PGE2, the $\alpha$ subunit is dissociated from the receptor and $\gamma$. See article by Yokoyama et al. on p. 1010 of this issue